Matrix Pharmacorp Private Ltd, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is ROFLUMILAST, with a corresponding US DMF Number 28440.
Remarkably, this DMF maintains an Active status since its submission on September 04, 2014, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of November 11, 2014, and payment made on August 04, 2014, indicating their dedication to facilitating drug approvals, Categorized as Type II